Failure of second-line ART is common in resource-limited countries, but modern third-line regimens work well
Another possible case of PrEP 'breakthrough' infection reported
How much 'PrEP-resistant' HIV is out there?
Ibalizumab, active against highly resistant HIV, now approved in US
HIV drug resistance now high enough to trigger a change in first-line treatment in eastern and southern Africa
Fostemsavir controls viral load in half of people with highly drug-resistant HIV
Boosted protease inhibitor and lamivudine provides effective maintenance treatment
